三生制药SSGJ-706注射液启动II期临床 适应症为非小细胞肺癌

新浪财经
Aug 29

药物临床试验登记与信息公示平台数据显示,沈阳三生制药有限责任公司的评估SSGJ-706单药或者联合治疗晚期非小细胞肺癌的开放、多中心II期临床研究已启动。临床试验登记号为CTR20253459,首次公示信息日期为2025年8月29日。该药物剂型为无菌注射液,用法为静脉输注,每3周给药1次,用药时程直至研究者判断不再有临床获益等情况。本次试验主要目的为评估SSGJ-706单药或联合治疗晚期非小细胞...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10